Pathogen: SARS-CoV-2

UKILD-Long COVID

United Kingdom
|
2021-2024
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Community
  • SARS-CoV-2
  • Post-COVID-19

COMEBAC 2

France
|
2021-2022
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • SARS-CoV-2
  • Post-COVID-19

Andreasson

Sweden
|
2021-2025
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Community
  • SARS-CoV-2
  • Post-COVID-19
  • Blood sample

Bridevaux

Switzerland
|
2021-2022
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Adolescents (12-17 years)
  • Hospital
  • SARS-CoV-2
  • Post-COVID-19

Aguilaniu

Canada France Martinique Switzerland
|
2022-2023
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • SARS-CoV-2
  • Post-COVID-19

DisCOVID

France
|
2021-2024
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • SARS-CoV-2
  • Post-COVID-19

FAPI CLIMATE

Netherlands
|
2022-2024
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Intensive care unit
  • SARS-CoV-2
  • Post-COVID-19
  • Blood sample

Petersen

Faroe Islands
|
2022-2022
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Adolescents (12-17 years)
  • Children (1-11 years)
  • Community
  • SARS-CoV-2
  • Post-COVID-19

EuCARE-SCHOOLS

Italy Portugal Mexico
|
2022-2024
  • Adults (18-64 years)
  • Adolescents (12-17 years)
  • Children (1-11 years)
  • Community
  • SARS-CoV-2
  • Acute COVID-19
  • Nasopharyngeal swab
  • Non pharmacological intervention

Pinchera

Italy
|
2023-2023
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Infectious diseases unit
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Monoclonal antibodies
  • Tixagevimab/Cilgavimab

Paraskevis

Greece
|
2022-2022
  • Elderly (≥65 years)
  • Fragile population
  • Outpatient clinic
  • Community
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Nirmatrelvir/Ritonavir
  • Molnupiravir

Orth

Germany
|
2022-2023
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Hospital
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Monoclonal antibodies
  • Nirmatrelvir/Ritonavir
  • Remdesivir
  • Sotrovimab
  • Molnupiravir
  • Tixagevimab/Cilgavimab
  • Casirivimab/Imdevimab